Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prexasertib and LY3300054 in Advanced Solid Tumors
NCT03495323Phase 1Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2018
- Primary completion
- Feb 2021
- Modality
- Prophylactic Vaccines, Monoclonal Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of prexasertib and lodapolimab in solid tumor (advanced stage), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Dose Limiting Toxicity at 2 years. Started May 2018; status: completed.
02
Drugs
prexasertiblodapolimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03495323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03495323.